Compare Revvity Inc (RVTY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs T Rowe Price Group Inc — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while T Rowe Price Group Inc trades at $115.59 (market cap $25.14B). The key difference: T Rowe Price Group Inc is far larger — about 2.1× Revvity Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.
| RVTY | TROW | |
|---|---|---|
Market Cap | $11.87B | $25.14B |
Sector | Technology | Financials |
52-Week High | $117.75 | $120.16 |
52-Week Low | $82.26 | $86.19 |
Enterprise Value | $14.36B | $21.85B |
Dividend Yield | 0.26% | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
T. Rowe Price (TROW) trades at $117.61, up 0.22% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $2.52, beating expectations, and maintains strong profitability with a 28.28% net margin. Recent news highlights the launch of an actively managed crypto ETF and AUM reaching $1.89 trillion in June 2026.
The stock presents a value opportunity with a P/E of 12.59, but faces mixed analyst sentiment with a consensus Hold rating. Upside potential exists if earnings momentum continues, while risks include market volatility impacting asset management fees and competitive pressures in the investment industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
